Basecamp Research has integrated its EDEN antibiotic design and vaccine target prediction models into Anthropic’s Claude Science platform, allowing researchers to generate and prioritise therapeutic candidates through a conversational interface.

The integration enables scientists to identify antibiotic candidates and prioritise vaccine targets using natural language, combining Claude’s reasoning capabilities with Basecamp’s biological foundation models.

The capability is available across Claude Science and other Claude platforms through Anthropic’s connectors directory.

The announcement builds on previous research conducted with the University of Pennsylvania, in which Basecamp reported that 97% of antibiotic peptides designed by EDEN showed activity against World Health Organization priority pathogens during laboratory testing. One candidate, EDEN-7, also demonstrated efficacy in mice infected with multidrug-resistant Acinetobacter baumannii.

Glen Gowers, co-founder and chief executive officer of Basecamp Research, said: “Microbes have been producing antibiotics and evolving resistance to each other for billions of years. EDEN learned from that history, and now, through Claude, researchers all over the world can design successful new antibiotics in minutes, not years.”

César de la Fuente, Presidential Associate Professor at the University of Pennsylvania, said: “This collaboration shows how frontier biological foundation models can be paired with rigorous experimental validation to accelerate antibiotic discovery.”

He added: “Antimicrobial resistance is one of the greatest existential threats facing humanity and collaborations like this between academia and industry are critical.”

The companies said the same approach can also support vaccine development by helping researchers prioritise protein targets from pathogen genome sequences, potentially reducing weeks of laboratory analysis.